Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depression Moderate Clear all
Terminated No phase listed Observational Accepts healthy volunteers

MRS and Medication Response: A Pilot Study

NCT03254342
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 6, 2026, 1:14 PM EDT
Terminated Phase 3 Interventional

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

NCT06514742
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

NCT00051259
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-Release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2010 · Synced Sep 6, 2026, 1:14 PM EDT
Terminated Not applicable Interventional Results available

Study of Respiratory Depression When Using a Hydromorphone Pain Protocol

NCT01784991
View directory record Official record
Conditions
Pain, Respiratory Depression
Interventions
Hydromorphone, Usual care group
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
60 Years to 90 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 6, 2026, 1:14 PM EDT
Recruiting Phase 3 Interventional

Nebulized Ketamine for the Treatment of Major Depressive Disorder

NCT06752759
View directory record Official record
Conditions
Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System Agents, Neurotransmitter Agents, Physiologic Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptom, Hypnotics and Sedatives, Anti-anxiety Agents, Tranquilizing Agents, Psychotropic Drugs, Anesthetics Agent
Interventions
nebulized ketamine, nebulized midazolam
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

NCT00566202
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Escitalopram, JNJ-18038683
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 6, 2026, 1:14 PM EDT
Recruiting Phase 3 Interventional

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

NCT07076407
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Dothan, Alabama • Huntsville, Alabama • Bentonville, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

NCT03307070
View directory record Official record
Conditions
Major Depressive Disorder, Traumatic Brain Injury
Interventions
Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

NCT00621946
View directory record Official record
Conditions
Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 1 Interventional Results available

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine Infusion plus RO DBT
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Not yet recruiting Phase 1 Interventional

Shortened LSD Intervention for Major Depressive Disorder

NCT07503002
View directory record Official record
Conditions
Major Depression Moderate, Major Depression Severe, Major Depression
Interventions
LSD, Risperidone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 4 Interventional

Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.

NCT00208715
View directory record Official record
Conditions
Major Depression, Mental Health
Interventions
Provigil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Stanford, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 3 Interventional

Effects Of Antidepressants On Sexual Functioning In Adults

NCT00051272
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 6, 2026, 1:14 PM EDT
Not yet recruiting Phase 2 Interventional

Ketamine Treatment for PTSD and MDD in TBI

NCT06228391
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder, Traumatic Brain Injury
Interventions
IV ketamine, Midazolam
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Dismantling Mindfulness: Contributions of Attention vs. Acceptance

NCT01831362
View directory record Official record
Conditions
Mild-moderate Unipolar Depression; Persistent Negative Affect
Interventions
Mindfulness-Based Cognitive Therapy, Focused Attention (FA), Open- Monitoring
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 6, 2026, 1:14 PM EDT
Completed No phase listed Observational

Combining Data Sources to Identify Effect Moderation for Personalized Mental Health

NCT05267873
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Duloxetine, Vortioxetine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 65 Years
Enrollment
9,586 participants
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Clinical Outcomes of a Digital Mental Health Intervention for Moderate/Severe Depression and Anxiety

NCT07081061
View directory record Official record
Conditions
Depression, Anxiety, Mental Health Issue, Mental Health Wellness 2
Interventions
BetterHelp
Other
Lead sponsor
Teladoc Health
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

NCT02942004
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 6, 2026, 1:14 PM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression

NCT04211467
View directory record Official record
Conditions
Depression, Clinical Depression, Depression, Anxiety, Depression, Postpartum, Depression, Endogenous, Depression in Remission, Depression Chronic, Depression Moderate, Depression Severe
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 6, 2026, 1:14 PM EDT
Recruiting Not applicable Interventional

Telehealth Behavioral Activation for Teens

NCT06273995
View directory record Official record
Conditions
Depression, Suicide and Self-harm, Depression in Adolescence, Depression Mild, Depression Moderate, Depression Severe
Interventions
Behavioral Activation
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Kintsugi Voice Device Pivotal Study

NCT06809907
View directory record Official record
Conditions
Depression, Depression Moderate, Depression Severe, Depression Mild
Interventions
Kintsugi Voice Device
Device
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Not applicable Interventional Results available

Preemie Hypothermia for Neonatal Encephalopathy

NCT01793129
View directory record Official record
Conditions
Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic, Hypoxic-Ischemic Encephalopathy, Ischemic-Hypoxic Encephalopathy
Interventions
Hypothermia, Normothermic Control
Device · Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
33 Weeks to 35 Weeks
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 6, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 6, 2026, 1:14 PM EDT